Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab After Marketing Approval in Spain

Launched by ASTRAZENECA · Jun 6, 2025

Keywords

ClinConnect Summary

This clinical trial is looking to understand how effective a medication called tezepelumab is in treating patients with severe asthma in Spain. The study will gather information from patients who have received at least one dose of tezepelumab since it was approved for use. Researchers want to see how well this treatment works for patients who have not been able to control their asthma symptoms with high-dose inhalers and other medications.

To be eligible for this study, patients must be at least 12 years old and have been diagnosed with severe asthma that isn’t well-managed with their current treatments. They also need to have been continuously enrolled in the healthcare data source for at least a year before starting the treatment and for three months afterward. It's important to note that if someone has participated in a clinical trial for asthma treatments in the past year or has tried multiple other asthma biologic treatments, they won't be eligible for this study. Participants will simply provide information about their experiences with the treatment, helping researchers learn more about its real-world effectiveness.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who received at least 1 tezepelumab dose after commercialization in Spain diagnosed with severe asthma who are inadequately controlled with high-dose inhaled corticosteroids and a long-acting β2-agonist ± additional medications for asthma control.
• • Patients aged ≥12 years at the index date.
• • Patients with continuous enrolment in the data source for at least 12-months before the index date.
• • Patients with at least three months of continuous enrolment in the data source after the index date.
• Exclusion Criteria:
• • Patients who received tezepelumab or any biologic drug for the treatment of asthma in a clinical trial at any time during the 12-months prior to the index date\*.
• • • Patients who had initiated 3 or more non-tezepelumab biologic treatment (omalizumab, mepolizumab, reslizumab, benralizumab and dupilumab) for severe asthma at any time prior to the index date).